Key result
Drug-eluting coronary stents may be associated with a small increased risk of late stent thrombosis compared with bare-metal stents.
Why the study?
Do drug-eluting coronary stents increase the risk of late stent thrombosis compared to bare-metal stents?
Do drug-eluting coronary stents increase the risk of late stent thrombosis compared to bare-metal stents?
Answers are grounded in this paper and cite their sources.
This editorial introduces a series of articles addressing the potential increased risk of late stent thrombosis associated with drug-eluting stents compared to bare-metal stents.
In this issue of the Journal, we publish five Original Articles and two Perspective articles on the subject of drug-eluting coronary stents.17 Our motivation is the recent concern that the implantation of drug-eluting stents, as compared with bare-metal stents, may be associated with a small increased risk of late stent thrombosis, a potentially fatal complication (Figure 1). At a meeting of the Circulatory System Devices Advisory Panel of the Food and Drug Administration (FDA) on December 7 and 8, 2006, presentations were made on virtually every aspect of this complex clinical problem.8 In order to inform the medical community, . . .
No takes yet. Share an insight, caveat, or question.
Curfman et al. (2007) conducted an editorial in Late stent thrombosis. Drug-eluting coronary stents vs. Bare-metal stents was evaluated on Late stent thrombosis. Drug-eluting coronary stents may be associated with a small increased risk of late stent thrombosis compared with bare-metal stents.
Synapse has enriched 10 related papers. Consider them for comparative context: